Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin

Younossi, Zobair M; Stepanova, Maria; Estep, Michael; Negro, Francesco; Clark, Paul J; Hunt, Sharon; Song, Qinghua; Paulson, Matthew; Stamm, Luisa M; Brainard, Diana M; Subramanian, G Mani; McHutchison, John G; Patel, Keyur

doi:10.1016/j.jhep.2015.08.027

Scientific article

English

Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin

ContributorsYounossi, Zobair M; Stepanova, Maria; Estep, Michael; Negro, Francesco; Clark, Paul J; Hunt, Sharon; Song, Qinghua; Paulson, Matthew; Stamm, Luisa M; Brainard, Diana M; Subramanian, G Mani; McHutchison, John G; Patel, Keyur

Published inJournal of hepatology, vol. 64, no. 1, p. 29-36

Publication date2016

Abstract

Hepatitis C virus (HCV) modulates host lipid metabolism for its replication and lifecycle. Our aims were to assess changes in the serum lipid and distal (post-squalene) cholesterol biosynthesis metabolite profile of HCV genotypes (GT) 2 and 3 patients treated with sofosbuvir+ribavirin.

Keywords

HCV
Sofosbuvir
Ribavirin
Lipid metabolism

Affiliation entities

Research groups

Etudes et traitement de l'hépatite C et B (554)

Citation (ISO format)

YOUNOSSI, Zobair M et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. In: Journal of hepatology, 2016, vol. 64, n° 1, p. 29–36. doi: 10.1016/j.jhep.2015.08.027

Article (Accepted version)

Identifiers

PID : unige:83791
DOI : 10.1016/j.jhep.2015.08.027
PMID : 26341824

Journal ISSN0168-8278

526views

3downloads

Creation15/01/2016 10:16:00

First validation15/01/2016 10:16:00

Update15/03/2023 00:21:22

Status update15/03/2023 00:21:22

Last indexation31/10/2024 03:24:29

Archive ouverte UNIGE

Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin

Hepatitis C virus (HCV) modulates host lipid metabolism for its replication and lifecycle. Our aims were to assess changes in the serum lipid and distal (post-squalene) cholesterol biosynthesis metabolite profile of HCV genotypes (GT) 2 and 3 patients treated with sofosbuvir+ribavirin.

Technical informations